☆ 4.3 Article

Adult medulloblastoma in an Australian population

JOURNAL OF CLINICAL NEUROSCIENCE (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Oncology

Molecular Targeted Therapies: Time for a Paradigm Shift in Medulloblastoma Treatment?

Lidia Gatto et al.

Summary: In the last decade, significant progress has been made in understanding the molecular biology of medulloblastoma, leading to the recognition of distinct molecular subgroups and the development of new clinical trials for updated treatment protocols. Medulloblastoma, previously considered a single disease, is now understood to be a heterogeneous tumor with different molecular subgroups that have varying gene expression profiles, pathogenetic driver alterations, clinical behaviors, and age at onset. Adult medulloblastoma, in particular, poses a challenge in neuro-oncology as there has been a lack of practice-changing clinical trials. The focus now is on translating the advances in cancer genomics into new molecularly targeted therapeutics to improve prognosis and treatment-related toxicities.

CANCERS (2022)

添加到收藏夹

Review Oncology

The Alliance AMBUSH Trial: Rationale and Design

Anita Mahajan et al.

Summary: Medulloblastoma, the most common embryonal tumor in children, can also arise in older patients. Clinical studies have helped understand molecular pathways and improved treatment strategies. Recent research has identified at least four subtypes of medulloblastoma, each potentially benefitting from specific therapies.

CANCERS (2022)

添加到收藏夹

Article Clinical Neurology

Medulloblastoma of the adult: results from a multicenter retrospective study by AINO (Italian Association of Neuro-Oncology) and SIN (Italian Society of Neurology)

Paola Gaviani et al.

Summary: Medulloblastoma is the most common primary malignant intracranial tumor in childhood, but rare in adults. A multicentric Italian study involving 10 centers showed that almost all patients underwent craniospinal irradiation after surgery, with adjuvant chemotherapy performed in 85.5% of patients. The overall survival rate at 5 years was 73.3%.

NEUROLOGICAL SCIENCES (2021)

添加到收藏夹

Article Clinical Neurology

Bevacizumab, irinotecan, and temozolomide with re-irradiation in adult recurrent medulloblastoma: A first case report

Takahiro Yamauchi et al.

Summary: This case report describes a 40-year-old male with recurrent medulloblastoma who remained stable for 6 months after re-irradiation and receiving multiple courses of bevacizumab, irinotecan, and temozolomide. This regimen may hold promise for recurrent medulloblastoma in adults, for which there is currently no effective therapy.

INTERDISCIPLINARY NEUROSURGERY-ADVANCED TECHNIQUES AND CASE MANAGEMENT (2021)

添加到收藏夹

Article Oncology

SEOM clinical guideline for management of adult medulloblastoma (2020)

R. Luque et al.

Summary: Recent advances in molecular profiling have reclassified medulloblastoma into at least four diseases with different prognostic factors and treatment responses. Management includes surgical resection, adjuvant therapy, and palliative treatment after relapse, with lifelong follow-up necessary for patients.

CLINICAL & TRANSLATIONAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Proton therapy for adult medulloblastoma: Acute toxicity and disease control outcomes

I. -C. Hia Liu et al.

Summary: Proton craniospinal irradiation in adult medulloblastoma patients is well tolerated, with promising disease control and survival outcomes. This data support the standard use of proton CSI for adult medulloblastoma.

JOURNAL OF NEURO-ONCOLOGY (2021)

添加到收藏夹

Review Oncology

The 2021 WHO Classification of Tumors of the Central Nervous System: a summary

David N. Louis et al.

Summary: The fifth edition of the WHO Classification of Tumors of the Central Nervous System integrates molecular diagnostics into CNS tumor classification, introduces different approaches to tumor nomenclature and grading, and emphasizes the importance of integrated diagnoses and layered reports.

NEURO-ONCOLOGY (2021)

添加到收藏夹

Review Oncology

Development of Randomized Trials in Adults with Medulloblastoma-The Example of EORTC 1634-BTG/NOA-23

Peter Hau et al.

Summary: This study focuses on medulloblastoma in post-pubertal patients, discussing its rarity, treatment options, and clinical trial design. By comparing treatment with SMO inhibitors for SHH subgroup patients, the aim is to improve treatment efficacy, reduce toxicity, and provide guidance for future clinical trials.

CANCERS (2021)

添加到收藏夹

Review Oncology

How we treat medulloblastoma in adults

E. Franceschi et al.

Summary: Medulloblastoma is a rare tumor in postpubertal patients and adults, with different subtypes having distinct prognoses and offering personalized treatment options. While multimodal therapies have shown good overall survival rates, therapeutic evidence from prospective randomized trials in adults is lacking. Treatment typically involves craniospinal chemoradiation followed by maintenance chemotherapy, with targeted therapies not yet widely implemented but showing promise for personalized approaches, particularly in the SHH subgroup. Regular clinical follow-up and monitoring are crucial for managing relapse and ensuring optimal outcomes for patients.

ESMO OPEN (2021)

添加到收藏夹

Article Oncology

Neurocognitive functioning and health-related quality of life in adult medulloblastoma patients: long-term outcomes of the NOA-07 study

Linda Dirven et al.

JOURNAL OF NEURO-ONCOLOGY (2020)

添加到收藏夹

Review Oncology

Personalized Medicine: Recent Progress in Cancer Therapy

Valentina Gambardella et al.

CANCERS (2020)

添加到收藏夹

Review Oncology

Proposed Additions to the NCCN Guidelines for Adult Medulloblastoma

Marta Penas-Prado et al.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)

添加到收藏夹

Review Oncology

Central Nervous System Cancers Version 3.2020

Louis Burt Nabors et al.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)

添加到收藏夹

Article Oncology

Outcomes of salvage re-irradiation in recurrent medulloblastoma correlate with age at initial diagnosis, primary risk-stratification, and molecular subgrouping

Tejpal Gupta et al.

JOURNAL OF NEURO-ONCOLOGY (2019)

添加到收藏夹

Article Oncology

EANO–EURACAN clinical practice guideline for diagnosis, treatment, and follow-up of post-pubertal and adult patients with medulloblastoma

Enrico Franceschi et al.

LANCET ONCOLOGY (2019)

添加到收藏夹

Review Health Care Sciences & Services

Medulloblastoma: optimizing care with a multidisciplinary approach

Alice Thomas et al.

JOURNAL OF MULTIDISCIPLINARY HEALTHCARE (2019)

添加到收藏夹

Article Oncology

Long-term outcomes of adult medulloblastoma patients treated with radiotherapy

Brian De et al.

JOURNAL OF NEURO-ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Multicenter pilot study of radiochemotherapy as first-line treatment for adults with medulloblastoma (NOA-07)

Dagmar Beier et al.

NEURO-ONCOLOGY (2018)

添加到收藏夹

Review Oncology

Cancer in Australia: Actual incidence data from 1982 to 2013 and mortality data from 1982 to 2014 with projections to 2017

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Phase I study of oral sonidegib (LDE225) in pediatric brain and solid tumors and a phase II study in children and adults with relapsed medulloblastoma

Mark W. Kieran et al.

NEURO-ONCOLOGY (2017)

添加到收藏夹

Review Clinical Neurology

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary

David N. Louis et al.

ACTA NEUROPATHOLOGICA (2016)

添加到收藏夹

Article Multidisciplinary Sciences

Divergent clonal selection dominates medulloblastoma at recurrence

A. Sorana Morrissy et al.

NATURE (2016)

添加到收藏夹

Editorial Material Oncology

Medulloblastoma in adults: they're not just big kids

Alvaro Lassaletta et al.

NEURO-ONCOLOGY (2016)

添加到收藏夹

Article Oncology

Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032

Giles W. Robinson et al.

JOURNAL OF CLINICAL ONCOLOGY (2015)

添加到收藏夹

Article Oncology

Late toxicity following craniospinal radiation for early-stage medulloblastoma

Kaitlin M. Christopherson et al.

ACTA ONCOLOGICA (2014)

添加到收藏夹

Article Oncology

Genome Sequencing of SHH Medulloblastoma Predicts Genotype-Related Response to Smoothened Inhibition

Marcel Kool et al.

CANCER CELL (2014)

添加到收藏夹

Article Oncology

Treatment of adult nonmetastatic medulloblastoma patients according to the paediatric HIT 2000 protocol: A prospective observational multicentre study

Carsten Friedrich et al.

EUROPEAN JOURNAL OF CANCER (2013)

添加到收藏夹

Article Medicine, General & Internal

Local perspective on a rare brain tumour: adult medulloblastoma

S. F. Wong et al.

INTERNAL MEDICINE JOURNAL (2013)

添加到收藏夹

Article Clinical Neurology

Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas

Marcel Kool et al.

ACTA NEUROPATHOLOGICA (2012)

添加到收藏夹

Article Oncology

Adult Medulloblastoma Comprises Three Major Molecular Variants

Marc Remke et al.

JOURNAL OF CLINICAL ONCOLOGY (2011)

添加到收藏夹

Article Oncology

High-dose chemotherapy with autologous stem cell transplantation in adults with recurrent embryonal tumors of the central nervous system

Paula Gill et al.

CANCER (2008)

添加到收藏夹

Article Oncology

Survival of patients with adult medulloblastoma - A population-based study

Rose Lai

CANCER (2008)

添加到收藏夹

Article Oncology

Characteristics and outcomes of medulloblastoma in adults

Celina Ang et al.

PEDIATRIC BLOOD & CANCER (2008)

添加到收藏夹

Article Oncology

Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma

Roger J. Packer et al.

JOURNAL OF CLINICAL ONCOLOGY (2006)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.